(509) 228-1000 WA
(208) 754-3100 ID

Cancer Treatment

Cancer Care Northwest Adds Optune Lua® for malignant pleural mesothelioma (MPM) to its array of cancer-fighting treatment options

Posted: July 20, 2022



Spokane, WA. – Recent medical advancements in oncology care are enhancing outcomes for cancer patients. Previously a treatment only available to patients with glioblastoma multiforme (GBM), Novocure has released Optune Lua®, an FDA-approved device indicated for the treatment of adult patients, with unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM) to be used together with standard chemotherapy (pemetrexed and platinum-based chemotherapy).

A group of Cancer Care Northwest (CCNW) physicians, Radiation Oncologists Dr. Bryan Ager, Dr. Robert Fairbanks, Dr. Corbin Jacobs, Dr. Wayne Lamoreaux, Dr. Christopher Lee, Dr. O. Kenneth Macdonald, Dr. Stephen Thatcher, and Dr. Aaron Wagner are certified providers. Offering this cutting-edge technology will enhance the quality of local medical care and add another component to the cancer-fighting treatment array CCNW provides.

Optune is a wearable, portable device that delivers treatment through ceramic discs within an adhesive bandage called “transducer arrays.” The transducer arrays are applied to the chest near where your cancer is located and the Optune device is powered on, Tumor Treating Fields (TTFields) are omitted to specifically target and disrupt the division of cancer cells. TTFields are low intensity (1-3 V/cm) alternating electrical fields tuned to a specific frequency (150 kHz) to disrupt solid tumor cancer cell division. This inhibits tumor growth and can possibly cause cancer cells to die, while sparing healthy cells.

For more information on Optune for GBM and MPM, click here.